Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.11, moving +1.63% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 0.11%.

Recursion Pharmaceuticals (NasdaqGS:RXRX) reports its first AI enabled clinical proof of concept in familial adenomatous polyposis. The company advances five clinical programs, signaling broader use ...

Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...

Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.37, moving +1.51% from the previous trading session. This move outpaced the S&P 500's daily loss of 0.28%. Elsewhere, the Dow ...

Recursion Pharmaceuticals had a busy start to the week, scrapping a rare disease asset from its pipeline as part of a strategic rethink while pulling in a $150 million private placement. The ...

Recursion Pharmaceuticals lacks any of the long history of consistent performance that Buffett favors. Nonetheless, it aspires to become a business with characteristics he might like. It'll take a few ...

Recursion Pharmaceuticals has agreed to acquire the Oxford, U.K.-based artificial intelligence (AI) drug pioneer Exscientia, the companies said today, in a deal that consolidates two leaders in ...

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...